As most know, I ran my first 5 years in honor of RJ, my patient partner. Numerous people have asked about the program and though I've written about it before, I wanted to mention it again. The Patient Partner program, and it's sister program - the In Memory Of program, are a part of the DFMC experience that only a limited number of runners experience firsthand. Runners are encouraged to apply to the programs, but there are a limited number of families that participate. The Patient Partners are kids going through or who have gone through cancer treatment at Dana-Farber and they choose to participate in the program. The In Memory Of program is similar, but participating families have lost a child to cancer. Both programs are incredibly moving and though RJ and I have "graduated" from the program, we have a lot of memories from our experience.
Running in honor and support of Chris Davie and his family as Chris battles glioblastoma. Fundraising to support The Claudia Adams Barr Program for Innovative Cancer Research at Dana-Farber while training for my 7th Boston Marathon with DFMC. We have raised over $83,000 during my previous 6 years and aim to surpass $100,000 this year!
About Me
- chris
- My Goal: Run the Boston Marathon on April 15, 2019 with the Dana-Farber Marathon Challenge. Raise $17,000 (or more!) where 100% of funds raised benefit the Claudia Adams Barr Program in Innovative Basic Cancer Research. I run in honor of my friend Chris Davie who is battling brain cancer. I also run in honor for my friend RJ and his continued cancer-free life, in memory of Heather Thomson, and for other family and friends who are or have battled cancer. Together we can help Dana-Farber Cancer Institute reach the ultimate finish line: a world without cancer
Barr Program Impact Statements
Barr Program Impact Statements
Immunotherapies: New Ways to Activate the Immune System—An important area of cancer research asks why the human body's defense systems do not always attack and destroy tumors as they form. Funded by the Claudia Adams Barr Program, Glenn Dranoff, MD, discovered complex regulatory pathways in the human immune system that cancers exploit in order to escape destruction. Reversal of these effects can lead to the development of vaccines against cancer, like Provenge for prostate cancer. This research has also enabled the development of immune-activating drugs such as ipilimumab, which showed striking effects in melanoma in a trial led by Dana-Farber scientists and is now approved by the Food and Drug Administration for treatment.
Wednesday, February 7, 2018
Patient Partners & Banners of Encouragement
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment